中新网北京4月17日电 记者今日从北京市医疗保障局获悉，为了进一步推动医药健康产业的创新发展，北京市政府积极布局，由市医疗保障局携手八个其他政府部门共同发布了《北京市支持创新医药高质量发展若干措施(2024)》。这一举措旨在加速医药健康产业的转型升级，培育新的经济增长点，以科技创新驱动医药产业的高质量发展。
《若干措施》涵盖了研发、生产、评审和应用的全过程，旨在通过政策引导和多部门协同，构建全方位、多层次的支持体系。措施中提出，将加大对创新医药研发的财政投入，优化审批流程，缩短新药上市时间，同时为创新医药产品提供更便捷的医保准入通道，以鼓励企业和科研机构加大创新力度。
北京市医疗保障局表示，这一系列政策的出台，旨在打造一个有利于创新的医药产业发展环境，激发市场活力，促进科技成果向现实生产力转化。通过政策的集成创新，北京市旨在形成一个政府、企业、科研机构共同参与，协同创新的医药健康产业发展新格局。
《若干措施》的实施，预示着北京市在医药健康产业的创新发展上迈出了坚实的一步，有望催生一批具有国际竞争力的创新医药企业，推动首都医药健康产业迈向更高水平。
英语如下：
News Title: “Beijing’s Multiple Departments Unite to Release ‘Several Measures’: Full-Chain Promotion of High-Quality Development in Innovative Pharmaceuticals”
Keywords: Beijing pharmaceutical innovation, policy support, high-quality development
News Content:
BEIJING, April 17 (Xinhua) – From the Beijing Municipal Medical Insurance Bureau, it was announced today that in an effort to further boost the innovative development of the pharmaceutical and healthcare industry, the Beijing municipal government has taken an active stance. Nine government departments, including the Medical Insurance Bureau, jointly released the “Beijing Municipal Measures for Supporting High-Quality Development in Innovative Pharmaceuticals (2024).” This initiative aims to accelerate the transformation and upgrading of the pharmaceutical and healthcare industry, nurturing new drivers of economic growth, and propel the high-quality development of the pharmaceutical sector with scientific and technological innovation.
The “Several Measures” encompass the entire process, from research and development to production, review, and application, with the goal of establishing a comprehensive and multi-level support system through policy guidance and inter-departmental collaboration. The measures propose increased financial input for innovative pharmaceutical R&D, streamlining approval procedures to shorten the time for new drugs to reach the market, and providing faster access to medical insurance coverage for innovative pharmaceutical products, thereby encouraging enterprises and research institutions to intensify their innovation efforts.
The Beijing Municipal Medical Insurance Bureau stated that these policy measures aim to create a favorable environment for the development of the innovative pharmaceutical industry, stimulate market vitality, and facilitate the transformation of scientific and technological achievements into productive forces. Through innovative policy integration, Beijing seeks to establish a new pattern of collaborative innovation in the pharmaceutical and healthcare industry, involving the government, enterprises, and research institutions.
The implementation of the “Several Measures” signifies a robust step forward for Beijing in the innovative development of the pharmaceutical and healthcare industry, with the potential to nurture a batch of internationally competitive innovative pharmaceutical companies and propel the capital’s pharmaceutical and healthcare sector to even higher standards.
【来源】http://www.chinanews.com/sh/2024/04-17/10200758.shtml
Views: 1